A recent report by insure-tech firm Plum has raised concerns about the adequacy of cancer insurance coverage in India. According to the study, health insurers in the country typically cover only 70.8% of total cancer treatment costs, leaving patients to bear a substantial financial burden despite having policies with coverage limits of Rs 10 lakh or more. This gap in coverage can lead to out-of-pocket expenses that may wipe out years of personal savings, highlighting the hidden risks associated with cancer treatment.
Cancer treatment in India involves a range of costs that often go beyond basic hospitalization. While standard insurance policies may cover surgery, chemotherapy, and radiotherapy to an extent, additional expenses such as advanced diagnostics, targeted therapies, immunotherapy, doctor consultation fees, and prolonged hospital stays are frequently excluded or partially reimbursed. Patients may also incur costs for post-treatment follow-ups, medications, and rehabilitation, which are rarely included under standard coverage.
Experts stress that patients should not assume that a high sum insured fully protects against all costs. “Many policyholders believe that Rs 10 lakh coverage is sufficient, but the reality of cancer treatment is far more expensive,” said an insurance analyst. The discrepancy between actual treatment expenses and policy payouts can leave families scrambling to manage finances during an already stressful period.
The Plum study also points out that policy terms, exclusions, and fine print play a significant role in determining the actual benefits a patient receives. Common exclusions include pre-existing conditions, alternative therapies, certain high-cost drugs, and experimental treatments. Patients are urged to carefully review policy documents, understand the scope of coverage, and consider top-up or critical illness riders that can extend protection beyond standard limits.
Financial planners advise combining insurance with personal savings and contingency funds to mitigate unexpected medical costs. In addition, selecting hospitals within the insurer’s network and opting for cashless treatment facilities can help reduce immediate out-of-pocket payments. Transparency in billing, prior approvals for expensive procedures, and regular communication with insurers are also critical to avoid surprises.
The findings of this report underscore a broader issue in India’s healthcare and insurance sectors: while insurance penetration is increasing, actual coverage and financial protection remain inadequate for serious illnesses like cancer. Policymakers and insurers are being called upon to design more comprehensive cancer insurance products that reflect real-world treatment costs and ensure financial security for patients.
Ultimately, patients and families must recognize that insurance alone may not be sufficient to cover all cancer-related expenses. Careful planning, awareness of hidden costs, and proactive engagement with insurance providers are essential to avoid financial distress during one of life’s most challenging medical crises. The Plum study serves as a wake-up call for policyholders to assess coverage realistically and prepare for unforeseen expenses in advance.
